NEW Product coming soon: COSMIC Actionability!
30 Sep 2020
We have recently launched The Cancer Mutation Census to much acclaim and success! But at COSMIC we never stop! Now we are working on our next product, Mutation Actionability in Precision Oncology!
What is Mutation Actionability in Precision Oncology?
The aim of the COSMIC Actionability resource is to capture the current state of precision oncology and comprehensively represent both, marketed drugs and drugs currently undergoing clinical trials, that target somatic mutations across all cancer types.
The principal units of actionability are mutation, disease, and drug. Capturing relations between these units allows identification of existing and upcoming drugs that target particular genetic variants in specific cancer types.
Our approach to actionability curation
- Clinical trial records
Freely available however often incomplete or outdated.
- Literature/journal articles
Our manual curation adds almost 60% more data into the resource than can be found using clinical trials databases alone. We aim to uncover why a clinical trial was withdrawn or terminated. We often include case studies, particularly for mutations that have not been investigated in trials.
- Company websites
We look for otherwise unpublished data in conference abstracts and corporate websites, to offer the fullest possible picture.
We include details of all trials submitted to the FDA for mutation-specific approved drugs.
Would you like to find out more?
If you are interested in finding out more and helping us improve the Actionability resource through user research participation, please email Charlie Hathaway, User Experience Lead on email@example.com
Keep up date to with COSMIC
Please follow us on LinkedIn, Twitter, Facebook and via our email announcements to keep abreast of the latest COSMIC news and developments. If you do not receive our emails, please update your email preferences, as shown below, in your COSMIC account.